Значок книги

RANOLAZINE IN ISCHEMIC HEART DISEASE

Показать другие версии (1)

Study results of a new anti-anginal drug (an inhibitor of sodium channels - ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.

Сохранить в:

Библиографические подробности
Главный автор:	V. P. Lupanov (Автор)
Формат:	‌
Опубликовано:	Столичная издательская компания, 2015-12-01T00:00:00Z.
Предметы:	article
Online-ссылка:	Connect to this object online.
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

RANOLAZINE IN ISCHEMIC HEART DISEASE
по: V. P. Lupanov
Опубликовано: (2015)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
по: V. P. Lupanov
Опубликовано: (2015)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
по: V. P. Lupanov
Опубликовано: (2015)

Mechanical effects of ranolazine on normal and diabetic-isolated rat heart
по: Hajar Khazraei, и др.
Опубликовано: (2021)

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
по: James A. Coleman, и др.
Опубликовано: (2024)

Emerging clinical role of ranolazine in the management of angina
по: David S Vadnais, и др.
Опубликовано: (2010)

Proton Dependent Inhibition of the Cardiac Sodium Channel Nav1.5 by Ranolazine
по: Stanislav eSokolov, и др.
Опубликовано: (2013)

Ischemic Heart Disease
Опубликовано: (2013)

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)
Опубликовано: (2015)

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)
Опубликовано: (2015)

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)
Опубликовано: (2015)

Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study
по: Shammas NW, и др.
Опубликовано: (2015)

Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels
по: Antonius Ratte, и др.
Опубликовано: (2019)

Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation
по: Julian Wolfes, и др.
Опубликовано: (2020)

Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations
по: Aziz Unnisa, и др.
Опубликовано: (2023)

Noise and ischemic heart disease
по: Jens Peter Bonde, и др.
Опубликовано: (2012)

ENDOTHELIAL DYSFUNCTION IN ISCHEMIC HEART DISEASE
по: N. E. Zakirova, и др.
Опубликовано: (2016)

Novel Strategies in Ischemic Heart Disease
Опубликовано: (2012)

The role of irisin in ischemic heart disease
по: Patrycja Agata Piątek, и др.
Опубликовано: (2019)

The role of irisin in ischemic heart disease
по: Patrycja Agata Piątek, и др.
Опубликовано: (2019)

MYOCARDIAL REMODELING IN ISCHEMIC HEART DISEASE
по: A. N. Zakirova, и др.
Опубликовано: (2016)

ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
по: F. I. Belyalov
Опубликовано: (2017)

MYOCARDIAL REMODELING IN ISCHEMIC HEART DISEASE
по: A. N. Zakirova, и др.
Опубликовано: (2016)

Familial Aggregation for Ischemic Heart Disease
по: José Leandro Pérez Guerrero, и др.
Опубликовано: (2022)

Curbing Inflammation in the Ischemic Heart Disease
по: Paulo Roberto B. Evora, и др.
Опубликовано: (2013)

RAMIPRIL EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION AND ISCHEMIC HEART DISEASE
по: A. I. Chesnikova, и др.
Опубликовано: (2016)

Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning
по: Sarah Rouhana, и др.
Опубликовано: (2021)

COMORBIDITIES IN PATIENTS WITH ISCHEMIC HEART DISEASE: GENDER DIFFERENCES
по: A. N. Sumin, и др.
Опубликовано: (2017)

The Clinical Outcome Comparison of Ischemic Stroke with and without Ischemic Heart Disease
по: Rizaldy Taslim Pinzon, и др.
Опубликовано: (2018)

NITRATES IN ISCHEMIC HEART DISEASE TREATMENT, YESTERDAY AND TODAY
по: S. N. Tereschenko, и др.
Опубликовано: (2015)

NITRATES IN ISCHEMIC HEART DISEASE TREATMENT, YESTERDAY AND TODAY
по: S. N. Tereschenko, и др.
Опубликовано: (2015)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
по: D. H. Aynetdinova, и др.
Опубликовано: (2015)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
по: D. H. Aynetdinova, и др.
Опубликовано: (2015)

THE POSSIBILITY OF USAGE OF METABOLIC CORRECTION THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND HEART FAILURE
по: I. V. Sergienko, и др.
Опубликовано: (2015)

THE POSSIBILITY OF USAGE OF METABOLIC CORRECTION THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND HEART FAILURE
по: I. V. Sergienko, и др.
Опубликовано: (2015)

IMMUNO-INFLAMATORY RESPONSE IN ISCHEMIC HEART DISEASE
по: N. E. Zakirova, и др.
Опубликовано: (2015)

IMMUNO-INFLAMATORY RESPONSE IN ISCHEMIC HEART DISEASE
по: N. E. Zakirova, и др.
Опубликовано: (2015)

Ischemic heart disease in Cuba. An update. 2015.
по: Nurys Armas Rojas Armas Rojas, и др.
Опубликовано: (2015)

Ischemic Heart Disease in the Context of Different Comorbidities
Опубликовано: (2022)

Health behavior of patients with ischemic heart disease
по: Paweł Węgorowski, и др.
Опубликовано: (2017)